[(3aR,4R,6R,6aR)-6-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2dimethyltetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methyl2methylpropanoate

This compound contains a protected ribose moiety linked to a pyrimidine base and is utilized during the multi-step synthesis to construct the nucleoside framework of the final active pharmaceutical ingredient. Through subsequent chemical transformations such as deprotection and functional group modification, this intermediate is converted into the desired antiviral molecule used for the treatment of COVID‑19. [(3aR,4R,6R,6aR)-6-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methyl 2-methylpropanoate is a key synthetic intermediate used in the preparation of the antiviral drug Molnupiravir.